226 Ledipasvir/Sofosbuvir With Ribavirin Is Safe in >600 Decompensated and Post Liver Transplantation Patients With HCV Infection: An Integrated Safety Analysis of the Solar 1 and Solar 2 Trials

2015 ◽  
Vol 148 (4) ◽  
pp. S-971 ◽  
Author(s):  
Michael R. Charlton ◽  
Didier Samuel ◽  
Michael P. Manns ◽  
Xavier Forns ◽  
Steven L. Flamm ◽  
...  
1998 ◽  
Vol 11 (0) ◽  
pp. S475-S480 ◽  
Author(s):  
M. De Bona ◽  
G. Rupolo ◽  
P. Ponton ◽  
R. M. Iemmolo ◽  
P. Boccagni ◽  
...  

2008 ◽  
Vol 22 (2) ◽  
pp. 153-154 ◽  
Author(s):  
Kymberly DS Watt ◽  
Kelly W Burak ◽  
Marc Deschênes ◽  
Les Lilly ◽  
Denis Marleau ◽  
...  

Allograft failure secondary to recurrence of hepatitis C virus (HCV) infection is the most common cause of death and retransplantation among recipients with HCV infection. It has been suggested that patients transplanted for HCV have had worse outcomes in more recent years than in previous years (the ‘era effect’). A Canadian transplantation registry database was analyzed to determine the outcomes of patients transplanted over the years for HCV. The results of the present analysis of 1002 patients show that the ‘era effect’ was not seen in liver transplantation recipients with HCV in Canada, because no survival difference was noted based on the year of transplantation. All groups had overall two-year and five-year survival rates of 76% to 83% and 69% to 72%, respectively. The present study’s national results prove continued benefit to transplantation of HCV patients.


Gut ◽  
2012 ◽  
Vol 61 (Suppl 2) ◽  
pp. A46.3-A47
Author(s):  
S M Noory ◽  
R Hajhosseiny ◽  
G Noory ◽  
D Joshi ◽  
A Quaglia

Sign in / Sign up

Export Citation Format

Share Document